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Myocardial extracellular volume fraction (ECV) assessed by cardiovascular magnetic 
resonance (CMR) estimates the extent of the myocardial extracellular space relative 
to its cellular component(1).  ECV measured by CMR is increased in a variety of 
diseases(2)(3) and has been validated against histologically derived myocardial 
ECV(4).  Furthermore, ECV shows promise in prognostication of mortality and 
morbidity(5)(6). Conventionally, ECV calculation requires knowledge of the patient’s 
hematocrit (Hct). Treibel et al.(7) recently demonstrated that a ‘synthetic ECV’ can be 
calculated by estimating Hct from the longitudinal relaxivity (R1 = 1/T1) of blood. This 
new approach to ECV estimation eliminates the time, cost and inconvenience 
associated with obtaining a venous Hct sample. So far, synthetic ECV has only been 
described for data acquired with a single vendor (Siemens) and field strength (1.5T). 
We hypothesised that synthetic ECV can also be derived from data acquired with other 
platforms and acquisition methods, which would further broaden the applicability of 
this method.  
In this single centre cross-sectional study, we analysed the data of 421 patients who 
had undergone T1 mapping for a mixture of research purposes and clinical indications, 
203 of whom underwent CMR scans on 1.5 Tesla (Philips Ingenia) and 218 on 3.0 
Tesla (Philips Achieva TX).  All clinical patients consented to having their data used 
for research prior to undergoing CMR examination.  All other patients gave informed 
written consent and were recruited with approval of the local ethics committee.  The 
study was conducted in accordance with the declaration of Helsinki.  Patients on both 
scanners were randomly split into equally sized derivation and validation subgroups.  
The derivation groups served to enable derivation of linear regression equations for 
the relationship of Hct and R1 of blood.  This equation was used to calculate synthetic 
ECV and assess its correlation with conventionally calculated ECV in the validation 
groups.  The 1.5 Tesla cohort comprised 47 patients with valvular heart disease and 
44 with ST-segment elevation myocardial infarction taking part in research studies and 
112 patients referred for CMR for clinical reasons.  The 3.0 Tesla cohort comprised 26 
healthy controls and 159 rheumatoid arthritis and 33 hypertrophic cardiomyopathy 
patients undergoing research CMR scans.  
Modified Look-Locker Inversion Recovery (MOLLI) sequences were used to produce 
T1 maps prior to and 15 minutes after administration of either 0.2 mmol/kg 
Gadopentate Dimeglucide (Magnevist, Bayer Schering) or 0.15 mmol/kg Gadobutrol 
(Gadovist, Bayer Schering).  T1 values were obtained by drawing a region of interest 
(ROI) within the interventricular septum and blood pool at mid-ventricular level using 
post-processing software (CVI 42, Circle Cardiovascular Imaging Calgary, Canada).  
Scar was included within the interventricular septum ROI when present.  Analysis was 
blinded.  Statistical analyses were performed using SPSS version 22 (Chicago, 
Illinois).  All results are presented as mean ± standard deviation.  
There was a broad range of Hct in both 1.5T and 3.0T derivation groups (0.41 ± 0.05, 
range 0.27 to 0.53 at 1.5T and 0.42 ± 0.04, range 0.31 to 0.54 at 3.0T).  There was 
also a broad range of blood T1 in 1.5T and 3.0T derivation groups (1608 ± 105 ms, 
range 1402 to 1912 ms at 1.5T and 1780 ± 99ms, range 1457 to 1993 ms at 3.0T).  
The conventionally calculated ECV in the validation groups was 32 ± 9 % (range 19 to 
77%) for 1.5T and 29 ± 5 % (range 20 to 53%) for 3.0T. 
The regression lines between Hct and R1 blood were linear at both field strengths 
(1.5T: R2 = 0.50, p = <0.001; 3T: R2 = 0.46, p = <0.001), resulting in the following 
regression equations (Figure 1): 
1.5T:  Synthetic Hct MOLLI = (922.6 · [1/T1blood]) – 0.1668 
3.0T:  Synthetic Hct MOLLI = (869.7 · [1/T1blood]) – 0.071 
Where Hct is hematocrit (between 0 and 1) and R1blood is 1/T1blood in milliseconds  
Using these linear regression equations to calculate synthetic ECV in both validation 
cohorts, conventional and synthetic ECV were highly correlated (Figure 1) (R2 = 0.95, 
p = <0.001 at 1.5T and R2 = 0.92, p= <0.01 at 3.0T). 
In the present study we demonstrate that synthetic ECV, derived by estimating the Hct 
from pre-contrast blood T1 values acquired with a MOLLI method on 1.5 and 3T Philips 
systems, strongly correlates with conventionally calculated ECV.  The correlation 
values we have demonstrated between Hct and R1 blood in the derivation cohort and 
between conventional and synthetic ECV in the validation cohort are very similar to 
those reported in the Treibel et al. on a Siemens platform using both MOLLI and 
ShMOLLI pulse sequences. This underscores the accuracy of synthetic ECV and its 
wide applicability across platforms and field strength.  It offers the potential for use on 
a routine clinical CMR list, eliminating the need for a venous Hct sample and thereby 
enabling rapid clinical decision-making. 
   
Figure 1. Panel A shows the linear correlation and regression equation between blood 
Hct and Blood R1 at 1.5 Tesla.  Panel B shows the linear correlation and regression 
equation between blood Hct and Blood R1 at 3.0 Tesla.  Panel C shows the linear 
correlation between conventional and synthetic ECV at 1.5 Tesla.  Panel D shows the 
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